Natco Pharma receives CDSCO approval for launch of Semaglutide in India
Natco Pharma received approval for Semaglutide from Central Drugs Standard Control Organisation (CDSCO) to manufacture and market generic Semaglutide Injection in India. NATCO will launch the product in the India market in March'26.
Semaglutide is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: Feb 14 2026 | 12:31 PM IST